The iRGD achieved tumor homing by initially binding to integrin αvβ3 and then being proteolytically cleaved to CRGDK/R, which can penetrate into tumor cells and tissues by binding with neuropilin-1. The gene discussed is NRP1; the disease is neoplasm.